A single, randomized, double-blind, controlled Phase 3 pivotal trial of Rezafungin or the treatment of candidemia and invasive candidiasis
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Rezafungin (Primary)
- Indications Candidaemia; Candidiasis
- Focus Adverse reactions; Registrational
- Acronyms ReSTORE
- Sponsors Cidara Therapeutics
- 15 Nov 2017 New trial record
- 08 Nov 2017 According to a Cidara Therapeutics media release, this and another Phase III trial (see profile 290391) could suffice for approval of rezafungin for both prophylaxis and treatment of invasive fungal infections.
- 08 Nov 2017 According to a Cidara Therapeutics media release, the company plans to initiate this trial in mid-2018, with topline data expected in mid-2020, subject to feedback from European regulators.